Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722917 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT00722917: Clinical Trial Phase 2 study, sponsored by Takeda.
NCT00722917 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 323 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722917, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG TAK-379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Why NCT00722917 stopped before completion
NCT00722917 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00722917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00722917 about?
NCT00722917 is a clinical study titled "Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00722917?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2008-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00722917?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), TAK-379 (DRUG).
Who is sponsoring clinical trial NCT00722917?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00722917's enrollment target sits among peer trials
323 150th of 2000 higher than 1,851 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia